Merck, BMS Prepare To Seek FDA Reversal On OTC Cholesterol Drugs
This article was originally published in The Tan Sheet
Executive Summary
Merck and Bristol-Myers Squibb are aiming to switch the lowest dosage levels of their respective Rx cholesterol-lowering drugs, Mevacor (lovastatin) and Pravachol (pravastatin), to OTC status. The firms have filed NDAs for approval of OTC 10 mg daily doses.